Amgen’s dazodalibep (a CD40 ligand antagonist) cleared the bar in preliminary Phase 3 results in Sjögren’s disease, with the company characterizing the data as statistically significant and clinically meaningful. The readout positions the fusion protein as a potential competitor to Novartis’s antibody in a disease category that still lacks approved targeted therapies.